MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

NCT00101179 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

NIH

Sponsor class

Conditions

Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndrome
Leukemia
Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Secondary Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine
DRUG: Entinostat

Sponsor

National Cancer Institute (NCI)